Keep Your Eyes on This Stock Alert: Translate Bio, Inc. (NASDAQ: TBIO)

On 07 May 2020, Translate Bio, Inc. stock identified change of 98.82% away from 52-week low price and recently located move of -9.87% off 52-week high price. It has market worth of $795.11M. TBIO stock has been recorded 37.19% away from 50 day moving average and 48.37% away from 200 day moving average. Moving closer, we can see that shares have been trading 17.91% off 20-day moving average.

Translate Bio (TBIO) recently reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019.

Fourth Quarter and Full Year 2019 Financial Results and Financial Guidance

Translate Bio ended the fourth quarter of 2019 with $188.7M in cash, cash equivalents and short-term investments and 60,022,067 shares of ordinary stock outstanding. The Company expects that its existing cash, cash equivalents and short-term investments will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2021.

Translate Bio stated a net loss of $31.0M and $6.0M for the three months ended December 31, 2019 and 2018, respectively, and a net loss of $113.3M and $97.4M for the years ended December 31, 2019 and 2018, respectively.

Alliance revenue was $3.9M and $1.2M for the three months ended December 31, 2019 and 2018, respectively, and $7.8M and $1.4M for the years ended December 31, 2019 and 2018, respectively. The alliance revenue was derived from the alliance and license contract that the Company entered into with Sanofi Pasteur in 2018. The increase was related to the advancement of the vaccine program during the year ended December 31, 2019 contrast to the same period in 2018.

Operating expenses for the three months ended December 31, 2019 were $35.6M, contrast to $8.5M for the same period in 2018, and were comprised of the following:

  • Research and development expenses of $25.0M during the fourth quarter of 2019, contrast to $17.2M for the same period in 2018. The increase is primarily Because of a raise in costs associated with the continued advancement of the Phase 1/2 trial of MRT5005 for the treatment of patients with CF and continued development of the vaccine programs as well as a raise in personnel-related costs.
  • General and administrative expenses of $7.3M during the fourth quarter of 2019, contrast to $5.9M for the same period in 2018. The increase is primarily Because of a raise in personnel-related costs and professional fees.
  • Operating expense of $3.3M for changes in the fair value of contingent consideration related to future potential milestone and earnout payment obligations. The operating expense was attributed to a raise in the fair value of the contingent consideration liability related to the CF program Because of its continued progress and the time value of money Because of passage of time.

Operating expenses for the year ended December 31, 2019 were $123.6M, contrast to $105.7M for the same period in 2018, and were comprised of the following:

  • Research and development expenses of $76.4M during the year ended December 31, 2019, contrast to $58.0M for the same period in 2018. The increase is primarilyBecause of a raise in costs associated with the continued advancement of the Phase 1/2 trial of MRT5005 for the treatment of patients with CF and continued development of MRT discovery and vaccine programs as well as a raise in personnel-related costs.
  • General and administrative expenses of $28.6M during the year ended December 31, 2019, contrast to $22.6M for the same period in 2018. The increase is primarilyBecause of a raise in personnel-related costs.
  • Operating expense of less than $0.1M for changes in the fair value of contingent consideration related to future potential milestone and earnout payment obligations, contrast to $25.0M for the same period in 2018. The operating expense in 2019 was attributed primarily to a raise in the fair value of the contingent consideration liability related to the CF program Because of its continued progress and the time value of money Because of passage of time offset by the decision to discontinue the ornithine transcarbamylase (OTC) deficiency program, which the Company discontinued in the third quarter of 2019 and which resulted in the removal of $23.2M in contingent consideration liability related to the OTC deficiency program.
  • An impairment charge of $18.6M representing the value of the indefinite-lived in-process research and development intangible asset related to the discontinuation of the OTC deficiency program.

The Healthcare sector company, Translate Bio, Inc. noticed change of 1.65% to $13.52 along volume of 459306 shares in recent session compared to an average volume of 476.82K. The stock observed return of 3.13% in 5 days trading activity. TBIO’s shares are at 77.66% for the quarter and driving a 48.08% return over the course of the past year and is now at 66.09% since this point in 2018.

 

Leave a Reply

Your email address will not be published. Required fields are marked *